Hepatitis C virus inhibitors

A compound of formula (I)

• or a pharmaceutically acceptable salt thereof, wherein
• n and m are each independently 0, 1, 2, or 3;
• R1 is selected from hydrogen, alkenyl, alkyl, and cycloalkyl, wherein the alkenyl, the alkyl, and the cycloalkyl are each optionally substituted with one, two, three, or four halo groups;
• each R2 and R3 are independently selected from alkoxy, alkyl, cyano, dialkylamino, halo, haloalkoxy, haloalkyl, and hydroxy;
• R4 is selected from hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclyl, and heterocyclylalkyl;
• wherein the alkyl and cycloalkyl are each optionally substituted with one group selected from alkoxy, haloalkoxy, halo, haloalkyl, cyano, and dialkylamino;
• R5 is selected from hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfonyl, haloalkoxycarbonyl, haloalkyl, haloalkylcarbonyl, (NRaRb)carbonyl, and (NRaRb)sulfonyl, wherein Ra and Rb are independently selected from hydrogen, alkoxy, alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, heterocyclyl, and heterocyclylalkyl;
• and
• Q is a C6-C9 saturated or unsaturated carbon chain.